

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7314976

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GENOMIDEA INC.	04/24/2022
RECEIVING PARTY DATA	
Name:	IMMUNOMEDICINE, INC.
Street Address:	1-3, BINGOMACHI 4-CHOME, CHUO-KU
City:	OSAKA-SHI, OSAKA
State/Country:	JAPAN
Postal Code:	541-0051
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	11166995
CORRESPONDENCE DATA	
Fax Number:	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(312) 616-5600
Email:	mgreer@leydig.com, assignments@leydig.com
Correspondent Name:	JOHN KILYK, JR.
Address Line 1:	LEYDIG, VOIT & MAYER, LTD.
Address Line 2:	TWO PRUDENTIAL PLAZA, SUITE 4900
Address Line 4:	CHICAGO, ILLINOIS 60601-6731
ATTORNEY DOCKET NUMBER:	743436
NAME OF SUBMITTER:	JOHN KILYK, JR.
SIGNATURE:	/John Kilyk, Jr./
DATE SIGNED:	05/05/2022
Total Attachments: 1	
source=Assignment-GenomIdeatoImmunomedicine#page1.tif	

ASSIGNMENT

WHEREAS, GenomIdea Inc. of 3-15, Edobori 1-chome, Nishi-ku, Osaka-shi, Osaka 550-0002 Japan (hereinafter referred to as Assignor), having been assigned its right, title and interest in the invention by virtue of an Assignment recorded at the U.S. Patent and Trademark Office on May 1, 2019, at Reel 049048, Frame 0508, co-owns, along with OSAKA UNIVERSITY, U.S. Patent No. 11,166,995, which issued on November 9, 2021, and is entitled "ANTICANCER AGENT COMPRISING HVJ-E AND IMMUNE CHECKPOINT PROTEIN INHIBITOR" (hereinafter referred to as Patent Property),

WHEREAS, Immunomedicine, Inc. of 1-3, Bingomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0051 Japan (hereinafter referred to as Assignee), is desirous of acquiring the entire right, title, and interest of Assignor in, to, and under the Patent Property,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor hereby sells, assigns and transfers to the Assignee the entire right, title, and interest of Assignor in, to, and under the Patent Property, including any and all rights to sue and seek damages for past infringement of the Patent Property, as well as any reissue, reexamination, or post-grant review thereof,

Assignor will not execute any writing or do any act conflicting with the terms of this Assignment, and Assignor will, upon request and at Assignee's expense, execute such additional documents and do such additional acts as may be necessary to perfect the Assignee's enjoyment of this Assignment,

Assignor further covenants that Assignee will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to Assignor and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to Assignee or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purpose thereof.

The terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto, and

U.S. law governs this assignment.

IN WITNESS WHEREOF, Assignor has caused one of its duly authorized officers to hereunder set his/her hand on the date shown below.

Date April 24, 2022



Name: Keizo Miyata
Title: Executive Director, President
Authorized Officer of
GenomIdea Inc.